VOLITIONRX LTD DL-,001 Forum: Community User: Moonhawk4

Immer wieder Interessant zu beobachten wie Wochenlang unter niedrigem Volumen der Kurs fällt und Unten mit großem Volumen aufgekauft wird . Ich erwarte mit Spannung die Ankündigung der ersten Lizenzverträge im Vet Bereich aber auch bei NuQ Nets !

Ups falsches Wirtschaftssystem ;)

Uns falsches Wirtschaftssystem;)

Auferstanden aus Ruinen und der Zukunft zugewandt...

Und er hat vor ein paar Tagen bereits gekauft. Heute kommt richtig Volumen in das Teil. Endlich mal wieder ein Anstieg mit Volumen. Gutes Zeichen, 2 Tage und wieder nett im plus 😍😍😍

Schnäppchen EK ;)

Finde ich auch 🤑

Das er so eine postition eingeht

Finde ich ein gutes Zeichen ,. DYOR

Vorstand hat sich für VolitionRX Aktien zugelegt,. DIRECTOR: Innes Guy Archibald 150,000 | $3.35 | $502,500

Den folgenden Beitrag bitte von oben nach unten lesen - oder zur Not im „WO“Forum, dort ist mir die Formatierung besser gelungen. (Hier werden leider keine Abstände übertragen und man ist von der Länge sehr begrenzt. )

Highlights Earning Call [ folgende Zitate sind nachzulesen auf Quelle: https://www.fool.com/earnings/call-transcripts/2021/05/12/volition-rx-limited-vnrx-q1-2021-earnings-call-tra/ ] „four key pillars, Nu.Q cancer, Nu.Q vet, Nu.Q nets and Nu.Q capture.“ Nu.Q Cancer – colorectal cancer has been caused and collection for the blood cancer study in the US has been slightly delayed (pandemic)and will give a full updated timeline in the near future – we are looking at ways, perhaps we can get things back on track time wise – we will have a full update as soon as we know and I strongly expect that's going to be before or after the next Q – In Asia, we have reached our target patient cohorts for both colorectal cancer studies and the lung cancer study – now be running the assays and finalizing the analysis over the coming months. With data due to be reported at future conferences. – focus on getting the blood cancer in humans product out first, because that is very close to product ready, because it is a very simple panel, and to be 100% upfront – we still have more work to do on the backgrounds of lung and colorectal, but given the optionality we thought we would go with where the very low hanging fruit is at the moment in the blood cancer, NETosis and the Vet space Nu.Q Vet – We are not putting a lot more on very much at all marketing in at the moment, because we are answering all these questions – Now $25,000 revenue – there has been good interest, but we are using this much -- there is no point spending huge marketing budget now, when I think we are going to look nationally launch with all the tweaks that we have been using. – i would expect it to rise but I think the big change will be after the national launch and I think if we can get a licensing deal that would absolutely supercharge – expected national Launch of Nu.Q Vet in the United States, in the next few month – our new commercial team is building a solid pipeline of sales opportunities – we are seeing a lot of interest in the Vet product on the licensing side – the Beta launch has captured the interest of a wide range of industry players wanting to license or distribute our platform – very large multinational companies we are currently in very active discussions with which if successfully concluded would help accelerate launches and sales worldwide – Dr. Tom Butera join the team to lead the efforts on that front

Nu.Q nets – Nu.Q net nucleosomes level strongly correlated with disease severity in the first wave of COVID-19 patients and mortality – additional studies in collaboration is to be announced soon – our Nu.Q assay was the best and most practical way to measure the net response – now progressing to investigate further animal models and our first human trial is under way now – there is several other areas of NETosis where we have been very active in supporting groups who have research going in that field with providing our assays and our knowledge of NETosis – we have been shipping kits to very busy, very independent people. And the feedback we have got has been nothing short of excellent in every case, not only in the quality of our assay, but how well it is at doing different things with regard to the NETosis – the data we have, we have a lot we haven't published, we are working on through now – So we are also working, putting the sepsis platform on beads, so it can be done in 45 minutes and also potentially point of care. So theoretically, you could have almost instantaneous measurement on the NETs level. – sepsis might be the one which is easiest to get the traction in. Certainly the easiest way to get large numbers in a trial – hoping in the future to license to groups like the big auto analyze the companies, there is about half a dozen of them at Roche, Siemens and then developed a point of care – NETosis were very simple couple of assays, which we can launch very quickly and easily – In the US, there is some talk of trying to get emergency use, which of course we try for the COVID. But I don't know, I think it is certainly less than 50/50, we would get that. – collect for a 510 (k) and then go through that path which Dr. Terrell has done quite a bit of work from in a range of areas. So the cost of that is a few million dollars typically. We tend to look at $2 million or $3 million and it usually takes up 12-months, 18-months for collection, plus all the regulatory timing from whenever we start the process, which we are working on now Nu.Q capture – NucleoCapture technology will be useful as a DNA enrichment technology which could aid diagnosis – showed that the use of Nu.Q Capture may open up the possibility of using mass spectrometry not only for biomarker discovery but also as a high throughput platform for screening and all diagnostics – anything which is going to be next year would not be an FDA study. It would be sold as a service for others to help them – would we work with big companies? Absolutely. So I guess there is one very well-known big sequencing company, and there's quite a few big companies in the liquid biopsy space. – once we have got the very good proof of concept from the next level, if that happens, we would quite aggressively look to license it out

Silver One – We are now producing recombinant nucleosomes in-house and at large scale – by the end of this month, we will also be producing our very own antibodies in house – Silver One is now I think there is 12 or 13 different recombinant nucleosomes we're producing. We could offer service for, I think, about 15 different nucleosome assays. So -- and potentially, you could Nu.Q Capture is a service as well, which could be the revenue next year. – we have installed a service lab in the new facility, which will undertake sampling processing for external parties, such as pharmaceutical companies, biotech companies and academic researchers. We have branded this service Nu.Q discover, and I have already generated much interest. We have commercial interest from and quotes into multiple pharma and biotech companies and anticipate revenue from this activity in the second quarter and growing throughout the year. We see this as another key driver of revenue. – we have signed our first distribution agreement with Biomedicaa, a distributor with over 40-years experience for the distribution of our CE mark Nu.Q Kit in Central and Eastern Europe Financial Statement – closed out the first quarter of 2021 with cash and cash equivalents of approximately $33.1 million – expect the cash burn rate going forward to average around $2 million per month

https://www.fool.com/earnings/call-transcripts/2021/05/12/volition-rx-limited-vnrx-q1-2021-earnings-call-tra/

Das macht extrem Sinn hinzu kommen wieder die komischen vollkommen undifferenzierten negative forenkommentare aus dem Nichts (darf man nicht unterschätzen bei so smallcaps kann man da schon was bewegen) und danke auch an physiq und jdjd gibt echt Leute die hier hellwach sind